ISOTYPE CHARACTERIZATION OF ANTI-INFLIXIMAB ANTIBODIES IN PEDIATRIC PATIENTS WITH RHEUMATIC DISEASES TREATED WITH INFLIXIMAB

被引：0
|
作者：
Kosmac, M. [1 ,2 ,3 ]
Toplak, N. [3 ]
Simonini, G. [4 ,5 ]
Cimaz, R. [4 ,5 ]
Serbec, V. Curin [1 ,2 ]
Avcin, T. [3 ]
机构：
[1] Blood Transfus Ctr Slovenia, Dept Prod Diagnost Reagents & Res, Ljubljana, Slovenia
[2] Univ Ljubljana, Fac Chem & Chem Technol, Ljubljana 61000, Slovenia
[3] Univ Childrens Hosp, Univ Med Ctr, Dept Allergol Rheumatol & Clin Immunol, Ljubljana, Slovenia
[4] Anna Meyer Childrens Hosp, Rheumatol Unit, Florence, Italy
[5] Univ Florence, Florence, Italy
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 71卷
关键词：
D O I：
10.1136/annrheumdis-2012-eular.2260
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：255 / 255
页数：1
相关论文
共 50 条
  • [41] Anti-infliximab antibodies are eliminated more rapidly in vivo than non-immune antibodies in the presence of infliximab
    Rojas, J
    Rutkoski, T
    Vennarini, J
    Jang, H
    Wagner, CL
    [J]. FASEB JOURNAL, 2003, 17 (07): : C138 - C138
  • [42] Anti-infliximab antibodies: How to compare old and new data?
    Imbrechts, Maya
    Van Stappen, Thomas
    Compernolle, Griet
    Tops, Sophie
    Gils, Ann
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2020, 177
  • [43] Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases
    Martinez-Feito, Ana
    Novella-Navarro, Marta
    Hernandez-Breijo, Borja
    Nozal, Pilar
    Peiteado, Diana
    Villalba, Alejandro
    Nuno, Laura
    Monjo, Irene
    Pascual-Salcedo, Dora
    Balsa, Alejandro
    Plasencia-Rodriguez, Chamaida
    [J]. RHEUMATOLOGY, 2024,
  • [44] TROUGH INFLIXIMAB LEVELS AND ANTI-INFLIXIMAB ANTIBODIES IN SPONDYLOARTHRITIS PATIENTS ON TREATMENT WITH LOW DOSE INFLIXIMAB: A SINGLE CENTRE CROSS-SECTIONAL STUDY
    Patil, A.
    Upadhyaya, S. K.
    Dawar, R.
    Vaishnav, B.
    Dadhaniya, N.
    Gupta, S. J.
    Handa, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1292 - 1292
  • [45] Anti-infliximab antibodies are eliminated more rapidly in vivo than non-immune antibodies in the presence of infliximab
    Rojas, J
    Rutkoski, T
    Vennarini, J
    Jang, H
    Wagner, CL
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 175 - 175
  • [46] Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response
    Haraoui, B
    Cameron, L
    Ouellet, M
    White, B
    [J]. JOURNAL OF RHEUMATOLOGY, 2006, 33 (01) : 31 - 36
  • [47] InfliximabDevelopment of anti-infliximab antibodies, rash and fever: case report
    [J]. Reactions Weekly, 2019, 1775 (1) : 259 - 259
  • [48] Therapeutic drug monitoring countering the effect of anti-infliximab antibodies
    Hooijberg, Femke
    Wolbink, Gertjan
    [J]. LANCET RHEUMATOLOGY, 2024, 6 (04): : e193 - e194
  • [49] Infliximab and anti-infliximab antibody levels in Crohn's disease
    Hendy, Philip
    [J]. FRONTLINE GASTROENTEROLOGY, 2014, 5 (04) : 227 - 228
  • [50] Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab
    Hernandez-Breijo, B.
    Chaparro, M.
    Cano-Martinez, D.
    Guerra, I.
    Iborra, M.
    Cabriada, J. L.
    Bujanda, L.
    Taxonera, C.
    Garcia-Sanchez, V.
    Marin-Jimenez, I.
    Barreiro-de Acosta, M.
    Vera, I.
    Martin-Arranz, M. D.
    Mesonero, F.
    Sempere, L.
    Gomollon, F.
    Hinojosa, J.
    Gisbert, J. P.
    Guijarro, L. G.
    [J]. BIOCHEMICAL PHARMACOLOGY, 2016, 122 : 33 - 41
12345